Johnson & Johnson (NYSE:JNJ) Shares Bought by Family Legacy Inc.

Family Legacy Inc. increased its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 0.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,482 shares of the company’s stock after purchasing an additional 198 shares during the quarter. Johnson & Johnson accounts for about 1.9% of Family Legacy Inc.’s holdings, making the stock its 10th largest holding. Family Legacy Inc.’s holdings in Johnson & Johnson were worth $4,934,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. PFG Investments LLC raised its holdings in Johnson & Johnson by 1.2% in the 4th quarter. PFG Investments LLC now owns 20,571 shares of the company’s stock worth $3,224,000 after purchasing an additional 238 shares during the period. Cultivar Capital Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $814,000. Trust Co of the South purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $1,817,000. Sherrill & Hutchins Financial Advisory Inc purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $339,000. Finally, Vision Capital Management Inc. grew its position in shares of Johnson & Johnson by 0.6% in the fourth quarter. Vision Capital Management Inc. now owns 50,965 shares of the company’s stock valued at $7,988,000 after purchasing an additional 294 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 28th. Morgan Stanley lowered their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $177.31.

Get Our Latest Report on JNJ

Johnson & Johnson Trading Up 0.1 %

Johnson & Johnson stock opened at $158.17 on Friday. The firm has a 50 day simple moving average of $158.71 and a 200-day simple moving average of $156.69. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The stock has a market capitalization of $381.15 billion, a PE ratio of 11.45, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period last year, the firm posted $2.35 earnings per share. The business’s revenue was down 9.7% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.01%. The ex-dividend date was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.